This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
A Few Reasons Why Small-Cap ETFs Are Good Bets Now
by Sanghamitra Saha
Small-cap ETFs show resilience amid war jitters, backed by domestic focus, lower energy risks for the United States, a steady Fed and earnings strength.
ETF Winners & Losers of Q1 2026
by Sanghamitra Saha
Iran war reshaped Q1 markets: energy, shipping & lithium ETFs surged while tech and airlines lagged as inflation fears and oil shocks rattled sentiment.
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?
by Sanghamitra Saha
Q4's top ETF winners -- silver, biotech and lithium -- outpaced markets. Can SIVR, SLV, BBC and LITP extend gains into 2026?
Biotech ETFs Hovering Around a 52-Week: Here's Why
by Sanghamitra Saha
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
Biotech ETFs Bounce Back in 2025: Here's Why
by Sanghamitra Saha
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
Test ETF Tickers 12/15
by Zacks Equity Research
Test ETF Tickers
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Why Biotech ETFs Are Beating the Market
by Neena Mishra
: Biotech stocks are poised to benefit from lower rates
Small-Cap ETFs to Rally on Upbeat U.S. Q2 GDP Growth Data?
by Sanghamitra Saha
The US economy expanded at a faster-than-expected pace in the second quarter of 2024. Small-cap stocks generally lead the way higher on improving American economy.